TY  - CONF

T1  - 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

JO  - Journal of Clinical Oncology

PY  - 2015/05/20

AU  - Parker C

AU  - Vogelzang NJ

AU  - Sartor AO

AU  - Coleman RE

AU  - Skjorestad I

AU  - Fang F

AU  - Nilsson S

ED  - 

DO  - DOI: 10.1200/jco.2015.33.15_suppl.e16102

PB  - American Society of Clinical Oncology (ASCO)

VL  - 33

IS  - 15_suppl

SP  - e16102

EP  - e16102

Y2  - 2025/10/10

ER  -